Jackson Wealth Management LLC Sells 1,960 Shares of Amgen Inc. (NASDAQ:AMGN)

Jackson Wealth Management LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 31.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,324 shares of the medical research company’s stock after selling 1,960 shares during the period. Jackson Wealth Management LLC’s holdings in Amgen were worth $1,127,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Capital Performance Advisors LLP bought a new position in Amgen in the 3rd quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the third quarter valued at about $29,000. Matrix Trust Co acquired a new position in shares of Amgen in the third quarter valued at approximately $36,000. Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen during the third quarter valued at $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 0.1 %

Shares of NASDAQ AMGN opened at $289.02 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a market cap of $155.36 billion, a P/E ratio of 37.01, a P/E/G ratio of 2.87 and a beta of 0.56. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The business has a 50-day simple moving average of $270.95 and a two-hundred day simple moving average of $303.82.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Research analysts anticipate that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.29%. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is 115.24%.

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. Redburn Partners lowered their price objective on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Sanford C. Bernstein assumed coverage on Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price on the stock. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price target on shares of Amgen in a research note on Friday, January 24th. Finally, Bank of America reaffirmed an “underperform” rating and set a $256.00 price target on shares of Amgen in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.